Press Releases
 
Myelodysplastic Syndrome Therapeutics Pipeline Analysis - Collaboration and Other Developments

United States, 27 July 2017 -- Myelodysplastic syndrome therapeutics pipeline is expected to grow primarily due to the increasing prevalence of the disease as a result of increasing exposure of general population to chemicals and radiation.

Myelodysplastic syndrome is a group of disorders in which unhealthy blood cells are formed with poor function. The cause of myelodysplastic syndrome is still unknown but it is assumed that myelodysplastic syndrome is caused by exposure to chemicals and radiations. The risk factors of myelodysplastic syndrome include smoking, environmental exposures, other cancers and genetic syndromes. The symptoms of myelodysplastic syndrome are anaemia, shortness of breath, unusual bleeding, petechiae and frequent infections. The symptoms of myelodysplastic syndrome usually occur in late stages, which results in late diagnosis of the disease. There are several types of myelodysplastic syndrome including refractory cytopenia with unilineage dysplasia, refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, refractory anemia with excess blasts and myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality. The diagnosis of myelodysplastic syndrome is done by blood tests and bone marrow testing. Myelodysplastic syndrome is treated by blood transfusions, medications and bone marrow stem cell transplant. Also, changing lifestyle habits can help in improving the life of patient.

Explore Report at: https://www.psmarketresearch.com/market-analysis/myelodysplastic-syndrome-therapeutics-pipeline-analysis

Many companies are developing drug for myelodysplastic syndrome which have shown promising result in clinical trials. Celgene Corporation is developing a drug by the name Luspatercept for the improvement of myelodysplastic syndrome. Luspatercept is being developed as a recombinant protein which acts as a TGF-beta superfamily protein inhibitor. It has also received an orphan drug designation for myelodysplastic syndrome and beta-thalassaemia by U.S. Food and Drug Administration (USFDA). Janssen Research & Development, LLC is developing Imetelstat, which is currently in a Phase III clinical trial. Imetelstat is a telomerase inhibitor and has received an orphan drug designation for myelodysplastic syndrome and myelofibrosis by USFDA. Kura Oncology, Inc. is developing Tipifarnib for myelodysplastic syndrome patients. It is currently in Phase II stage of development and is a small molecule that inhibits farnesyltranstransferase. Pfizer Inc. is developing PF-04449913, which is in Phase II clinical trial and is a smoothened (SMO) protein inhibitor.

Request for table of Content at: https://www.psmarketresearch.com/market-analysis/myelodysplastic-syndrome-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of myelodysplastic syndrome therapeutics include Celgene Corporation, Janssen Research & Development, LLC, Onconova Therapeutics, Inc., Astex Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., GlaxoSmithKline Plc, AbbVie, Inc., Genentech, Inc., Kura Oncology, Inc., Boehringer Ingelheim GmbH, Novartis AG, Syros Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc., Acceleron Pharma, Inc., Pfizer Inc.

# # #


Submitted by Jacob, P&S Market Research on Thursday, 27 July 2017 at 6:35 PM
Category: Science & Research
 
Related News

Superabsorbent Polymers Market to Touch US$ 8.1 Bn by 2025
Monday, 19 Feb 2018

Tracking Ocean Salinity from Space using Colour
Monday, 19 Feb 2018

Stem Cells Market to Become Worth US$270.5 bn by 2025
Saturday, 17 Feb 2018

Hysteroscopes Market will Expand at a CAGR of 6.0% and Touch US$3.55 bn by 2025
Thursday, 15 Feb 2018

Rolling in it: Dung Beetles' Taste Preferences Uncovered
Friday, 9 Feb 2018

Related Events

Military Space Situational Awareness 2018
Wednesday, 25 Apr 2018

Disruptive Sustainability Technologies Conference
Wednesday, 18 Jul 2018

Latest News

Search For Restaurants In Killeen, TX
Saturday, 24 Feb 2018

Ripple Side Office Rental Offering Virtual Office Space on Rent
Saturday, 24 Feb 2018

North Geelong Glass – Best Options for Window Repairing
Saturday, 24 Feb 2018

Mazda Dealers - A Mazda Selection is the Correct 1
Saturday, 24 Feb 2018

Buy the Best Workout Benches Online
Saturday, 24 Feb 2018

 
Want to get your press releases, event listings, and job ads on Scoopasia? Register now for a FREE account or login if you already have one!
Scoopasia v1.0b. Copyright © 2018
Today is Saturday, 24 February 2018

About Scoopasia | FAQ | Privacy Policy | Contact Us

Press Releases
Event Listings
Job Listings
Arts & Entertainment
Architecture & Construction
Automotive & Travel
Business
Consumer Technology
Economy
Education
Enterprise Technology
Food & Fashion
Government & Policy
Health Care & Medical
Legal/Law
News & Media
Religion
Science & Research
Sports & Fitness
Login / Register
Get Scoopasia through RSS Feeds & Email Notifications!


Journalist's Toolbox
Hello journalist, welcome to Scoopasia--a powerful online resource for media information in Asia. Scoopasia has press releases and media events for every beat and industry. All content on Scoopasia is 100% FREE. You don't even need to login!

  • Scoop Line
    (Instant Information Request)
    The easiest way to ask questions and request information from the PR community.


  • Advanced Search
    Drill down, dig deep, for media information the way you want it.

  • Journalist's Resources
    Resources and tools you can't do without.

  • PR Tools
    Scoopasia Blog Search
    Search the largest handpicked collection of Asia's most prominent and influential blogs.


    Resources
  • PR Bookmarks
  • Web 2.0 Bookmarks
  • Media Bookmarks

    More Coming Soon...

  • Upcoming Events
  • Winter Wilderness First Aid Certification - Colorado
  • Collaborative 3D Printing in Medical Practice
  • The Great Plains Laboratory Presents GPL Academy Practitioner Workshops
  • The National Conference on Wilderness Medicine Big Sky Winter
  • Neuroepigenetics and Neuroepitranscriptomics Conference, Mexico, 2018

  • Latest Jobs
    Sorry, there are currently no entries posted here.